AI 聊天
正在加载 ACONW 的数据(首次访问,需要几秒钟)。

Aclarion, Inc.

ACONW · NasdaqCM · USD

0.03 +0.00 (0.00%)

收盘价: Oct 05, 2026, 3:25 PM EDT

市值
—

Aclarion, Inc.(ACONW)股价、分析与数据

时间间隔:1D
正在加载K线和信号…

内在价值

估值模型属于 Pro 功能。登录或升级后可查看完整分析。

查看方案 →

分析师预测

股票预测 →

分析师预测不可用

12个月目标价 · n/a 位分析师

分析师一致意见: n/a

您正在查看免费概览

创建免费账户,探索更多关于此标的的研究资料。

财务表现

查看财务 →

加载中...

最新财报

已公布较预期同比变动
营收—n/an/a
每股收益(TTM)—n/an/a

下次财报

查看财报详情 →

指标

买价
n/a
市值
n/a
净利润(TTM)
-9.2M
1.21
-6.58
n/a
n/a
市净率(TTM)
0.00
市销率(TTM)
n/a
财报日期
n/a
卖价
n/a
成交量
136,129
20日均量
n/a
开盘价
0.05
前收盘价
0.03
日内区间
0.02 - 0.03
52周区间
0.02 - 0.03
分红
n/a
除息日
n/a

关于 Aclarion, Inc.

查看公司资料 →
Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and imaging data transfer products, including AMBRA Healthcare, a data transfer platform. In addition, the company offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes the NOCICALC results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs examined in the patient. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado. ·

Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and imaging data transfer products, including AMBRA Healthcare, a data transfer platform. In addition, the company offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes the NOCICALC results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs examined in the patient. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

行业
板块
上市日期 Jul 17, 2026
员工人数 10
交易所 NasdaqCM
股票代码 ACONW